Investor Relations

Press Releases

All Releases
View Summary OPKO to Discuss Draft Coverage Determinations for 4Kscore® Test at 2016 Jefferies Healthcare Conference
Jun 7, 2016
PDF 15.9 KB
View Summary OPKO Health to Present at the 2016 Jefferies Healthcare Conference
Jun 2, 2016
PDF 11.7 KB
View Summary OPKO Health Receives Proposed/Draft Medicare Local Coverage Determination for 4Kscore® Test
May 27, 2016
PDF 15.3 KB
View Summary OPKO Announces Appointment of Douglass Laidlaw as Vice President of Medical Affairs
May 11, 2016
PDF 12.1 KB
View Summary OPKO Announces Appointment of Thomas Nusbickel as Senior Vice President of Pharmaceutical Marketing and Market Access
May 10, 2016
PDF 12.2 KB
View Summary OPKO Health Reports First Quarter Financial and Operating Results
May 9, 2016
PDF 32.4 KB
View Summary Vifor Fresenius Medical Care Renal Pharma and OPKO Health Enter into Agreement for OPKO's RAYALDEE®
May 9, 2016
PDF 23.1 KB
View Summary OPKO to Announce First Quarter Operating and Financial Results on May 9, 2016
Apr 28, 2016
PDF 13.6 KB
View Summary OPKO Presents Additional Data on RAYALDEE® at National Kidney Foundation Spring Clinical Meetings 2016
Apr 28, 2016
PDF 16.9 KB
View Summary FDA Accepts Resubmission of New Drug Application for RAYALDEE®
Apr 27, 2016
PDF 16.5 KB
View Summary OPKO Announces Appointment of James DeMarco as Senior Vice President of Pharmaceutical Sales
Apr 25, 2016
PDF 14.2 KB
View Summary OPKO Presents Additional Data on RAYALDEE® at ENDO 2016
Apr 1, 2016
PDF 17.5 KB
View Summary OPKO Presents Additional Data on RAYALDEE® to Treat Secondary Hyperparathyroidism in Chronic Kidney Disease
Mar 31, 2016
PDF 16.3 KB
View Summary OPKO Receives Complete Response Letter from FDA for RAYALDEE® New Drug Application
Mar 30, 2016
PDF 20.8 KB
View Summary OPKO Health Announces Executive Appointment
Mar 28, 2016
PDF 14.1 KB
View Summary OPKO To Present 18-24 Month Clinical Data on its Long-acting Human Growth Hormone (hGH-CTP) from Open Label Extension (OLE) Phase 2 Pediatric Growth Hormone Deficiency Clinical Study in Oral Presentation at ENDO 2016
Mar 24, 2016
PDF 22.4 KB
View Summary OPKO Health Announces Dosing of First Subject in Phase 1 Clinical Study of a Long-Acting Oxyntomodulin for the Treatment of Obesity and Type II Diabetes
Mar 16, 2016
PDF 13.7 KB
View Summary OPKO 4Kscore® Recommended in 2016 European Association of Urology Prostate Cancer Guidelines
Mar 15, 2016
PDF 14.9 KB
View Summary OPKO Health Names Dr. Gregory Henderson President of Bio-Reference Laboratories
Mar 15, 2016
PDF 17.2 KB
View Summary OPKO Health to Present at the 2016 Barclays Global Healthcare Conference
Mar 7, 2016
PDF 11.6 KB
Showing 61-80 of 344 Page: 1 2 3 4 5 6 7 8 ... 18  Previous 20 | Next 20

Email  Sign up for email alerts